US FDA approves Pfizer's nasal spray for migraine
Reuters
Published Mar 10, 2023 07:55AM ET
Updated Mar 10, 2023 03:11PM ET
By Khushi Mandowara
(Reuters) -The U.S. Food and Drug Administration on Friday approved Pfizer Inc (NYSE:PFE)'s nasal spray for migraine, giving patients access to a potentially fast-acting pain-relief option for headaches.
The drug, Zavzpret, was approved for the treatment of acute migraine, the company said. Pfizer gained the drug as well as FDA-approved oral migraine pill Nurtec ODT, through its $11.6 billion buyout of Biohaven Pharmaceutical last year.
Pfizer has forecast peak sales from its migraine pipeline to be around $6 billion.
Zavzpret, to be launched in July, would be comparable in price to other FDA-approved migraine medicines that belong to the same class of drugs, Pfizer told Reuters.
The drug, also known as zavegepant, will be competing with rivals from AbbVie Inc (NYSE:ABBV), Eli Lilly (NYSE:LLY) and Co, Amgen Inc (NASDAQ:AMGN) and Teva Pharmaceutical (NYSE:TEVA) that are also calcitonin gene-related peptide (CGRP) inhibitors.
"The (Pfizer) drug has two main advantages over the older CGRP antagonists: it is safe for people with cardiovascular risk factors, and second, it does not cause medication overuse headache," said Dr Emad Estemalik, psychiatrist at Cleveland Clinic.
A nasal spray would also benefit patients who are unable to swallow a pill, Estemalik said.
Pfizer is hoping to gain a competitive edge in the migraine drug category with Zavzpret, which Biohaven has called the "Epipen of migraine", for its quick action.
Zavzpret's approval was based on late-stage study data that showed the drug was superior in 13 of 17 goals when compared to placebo, including pain relief in 15 minutes and normal function at 30 minutes.
About 39 million people in the United States suffer from migraine, according to the Migraine Research Foundation.
Pfizer's shares were marginally up at $39.75 in noon trading.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.